Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.

Abstract

Basilea Pharmaceutica is developing BAL-8557, a water-soluble prodrug of the triazole BAL-4815, for the potential treatment of fungal infections. By August 2005, a phase II study in oral candidiasis was underway. In September 2005, phase III trials were planned for invasive Candida and mold infections, including aspergillus and zygomycetes.

• Authors: Frank C Odds
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 7 Issue 8 Pg. 766-72 (Aug 2006) ISSN: 1472-4472 [Print] England
• PMID: 16955689 (Publication Type: Journal Article, Review)

Chemical References

• Antifungal Agents
• Nitriles
• Pyridines
• Triazoles
• isavuconazole

Topics

• Animals
• Antifungal Agents (adverse effects, pharmacokinetics, pharmacology)
• Aspergillosis (drug therapy)
• Aspergillus (drug effects)
• Candida (drug effects)
• Candidiasis (drug therapy)
• Clinical Trials, Phase II as Topic
• Drug Evaluation, Preclinical
• Drug-Related Side Effects and Adverse Reactions
• Humans
• Nitriles (adverse effects, pharmacokinetics, pharmacology)
• Pyridines (adverse effects, pharmacokinetics, pharmacology)
• Triazoles (adverse effects, pharmacokinetics, pharmacology)